These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 12942155)
1. Predictive toxicology in drug development. Norman P Drug News Perspect; 2003 May; 16(4):254-6. PubMed ID: 12942155 [TBL] [Abstract][Full Text] [Related]
2. Early toxicity screening strategies. Greene N; Naven R Curr Opin Drug Discov Devel; 2009 Jan; 12(1):90-7. PubMed ID: 19152217 [TBL] [Abstract][Full Text] [Related]
3. Quantitative structure-activity relationship models for predicting drug-induced liver injury based on FDA-approved drug labeling annotation and using a large collection of drugs. Chen M; Hong H; Fang H; Kelly R; Zhou G; Borlak J; Tong W Toxicol Sci; 2013 Nov; 136(1):242-9. PubMed ID: 23997115 [TBL] [Abstract][Full Text] [Related]
4. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. Bender A; Scheiber J; Glick M; Davies JW; Azzaoui K; Hamon J; Urban L; Whitebread S; Jenkins JL ChemMedChem; 2007 Jun; 2(6):861-73. PubMed ID: 17477341 [TBL] [Abstract][Full Text] [Related]
5. Computational toxicology in drug development. Muster W; Breidenbach A; Fischer H; Kirchner S; Müller L; Pähler A Drug Discov Today; 2008 Apr; 13(7-8):303-10. PubMed ID: 18405842 [TBL] [Abstract][Full Text] [Related]
7. Toxicological and clinical computational analysis and the US FDA/CDER. Benz RD Expert Opin Drug Metab Toxicol; 2007 Feb; 3(1):109-24. PubMed ID: 17269898 [TBL] [Abstract][Full Text] [Related]
8. Comprehensive summary--Predict-IV: A systems toxicology approach to improve pharmaceutical drug safety testing. Mueller SO; Dekant W; Jennings P; Testai E; Bois F Toxicol In Vitro; 2015 Dec; 30(1 Pt A):4-6. PubMed ID: 25450741 [TBL] [Abstract][Full Text] [Related]
9. The impact of assay technology as applied to safety assessment in reducing compound attrition in drug discovery. Thomas CE; Will Y Expert Opin Drug Discov; 2012 Feb; 7(2):109-22. PubMed ID: 22468913 [TBL] [Abstract][Full Text] [Related]
10. In silico toxicology for the pharmaceutical sciences. Valerio LG Toxicol Appl Pharmacol; 2009 Dec; 241(3):356-70. PubMed ID: 19716836 [TBL] [Abstract][Full Text] [Related]
11. Trends in early drug safety. Armer RE; Morris ID Drug News Perspect; 2004 Mar; 17(2):143-8. PubMed ID: 15098069 [TBL] [Abstract][Full Text] [Related]
12. In silico modeling for prediction of drug-induced adverse reactions and environmental hazards using QSAR tools. Saha A; Roy K Curr Drug Saf; 2012 Sep; 7(4):255-6. PubMed ID: 23278211 [No Abstract] [Full Text] [Related]
13. Applying mechanisms of chemical toxicity to predict drug safety. Guengerich FP; MacDonald JS Chem Res Toxicol; 2007 Mar; 20(3):344-69. PubMed ID: 17302443 [TBL] [Abstract][Full Text] [Related]
14. Organic chemistry in drug discovery. MacCoss M; Baillie TA Science; 2004 Mar; 303(5665):1810-3. PubMed ID: 15031494 [TBL] [Abstract][Full Text] [Related]
15. Impact of computational structure-based predictive toxicology in drug discovery. Mohan CG Comb Chem High Throughput Screen; 2011 Jun; 14(5):417-26. PubMed ID: 21470184 [TBL] [Abstract][Full Text] [Related]
16. Analysis of Pfizer compounds in EPA's ToxCast chemicals-assay space. Shah F; Greene N Chem Res Toxicol; 2014 Jan; 27(1):86-98. PubMed ID: 24328225 [TBL] [Abstract][Full Text] [Related]
17. Anticancer Drug Development: The Way Forward. Connors T Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985 [TBL] [Abstract][Full Text] [Related]
18. Is the pharmaceutical industry's preoccupation with the monotherapy drug model stifling the development of effective new drug therapies? Cock IE Inflammopharmacology; 2018 Jun; 26(3):861-879. PubMed ID: 29736688 [TBL] [Abstract][Full Text] [Related]
19. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
20. Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery - the GSK experience. Vanderwall DE; Yuen N; Al-Ansari M; Bailey J; Fram D; Green DV; Pickett S; Vitulli G; Luengo JI; Almenoff JS Drug Discov Today; 2011 Aug; 16(15-16):646-53. PubMed ID: 21601652 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]